Skip to main content
Erschienen in: Medical Oncology 6/2014

01.06.2014 | Original Paper

Survival following primary androgen deprivation therapy for localized intermediate- or high-risk prostate cancer: comparison with the life expectancy of the age-matched normal population

verfasst von: Kazuhiro Matsumoto, Masayuki Hagiwara, Nobuyuki Tanaka, Nozomi Hayakawa, Masaru Ishida, Akiharu Ninomiya, Yosuke Nakajima, So Nakamura

Erschienen in: Medical Oncology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

The representative guidelines do not recommend androgen deprivation therapy (ADT) as a primary treatment for localized prostate cancer. However, in clinical practice, the use of primary ADT for localized prostate cancer has been widespread, especially among older patients. We performed a retrospective review of the efficacy of primary ADT for localized prostate cancer and compared their outcomes with the life expectancy of the normal population. The study cohort consisted of 410 men diagnosed with localized intermediate- or high-risk prostate cancer over the period 1992–2012 at five institutions. All patients underwent ADT as a primary cancer therapy, and mean follow-up was 6.0 years. Their progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) rates were calculated. Patients’ expected survival rates were estimated by the Hakulinen method. Multivariate analysis demonstrated that Gleason score ≥8 and cT3a were independent risk factors for all of PFS, CSS, and OS. In patients who have none or one of these risk factors, minimum OS rates were not inferior to the expected survival curves of the normal population. Meanwhile, in patients with both risk factors, the OS curve fell below the expected survival rates, especially after 6 years of follow-up. We conclude that primary ADT might be one of the therapeutic options for localized intermediate- and high-risk prostate cancer. However, for high-risk cases with Gleason score ≥8 and cT3a, the choice of primary ADT should be deliberated carefully because the OS of these cases was inferior to the expected survival, especially at a late time point.
Literatur
1.
Zurück zum Zitat The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol. 1997;79:235–46.CrossRef The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol. 1997;79:235–46.CrossRef
2.
Zurück zum Zitat National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guideline) prostate cancer, version 4. 2013. Fort Washington, PA. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guideline) prostate cancer, version 4. 2013. Fort Washington, PA.
3.
Zurück zum Zitat Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. European Association of Urology (EAU) guidelines on prostate cancer, 2013 edition, Arnhem, the Netherlands. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. European Association of Urology (EAU) guidelines on prostate cancer, 2013 edition, Arnhem, the Netherlands.
4.
Zurück zum Zitat Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003;95:981–9.PubMedCentralPubMedCrossRef Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003;95:981–9.PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol. 2005;12:46–61.CrossRef Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol. 2005;12:46–61.CrossRef
6.
Zurück zum Zitat Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer. 2006;106:1708–14.PubMedCrossRef Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer. 2006;106:1708–14.PubMedCrossRef
7.
Zurück zum Zitat Schymura MJ, Kahn AR, German RR, Hsieh MC, Cress RD, Finch JL, et al. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer. 2010;10:152.PubMedCentralPubMedCrossRef Schymura MJ, Kahn AR, German RR, Hsieh MC, Cress RD, Finch JL, et al. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer. 2010;10:152.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–64.PubMedCrossRef Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–64.PubMedCrossRef
9.
Zurück zum Zitat Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–56.PubMedCrossRef Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–56.PubMedCrossRef
10.
Zurück zum Zitat D’Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420–5.PubMedCrossRef D’Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420–5.PubMedCrossRef
11.
Zurück zum Zitat Hu JC, Williams SB, O’Malley AJ, Smith MR, Nguyen PL, Keating NL. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol. 2012;61:1119–28.PubMedCentralPubMedCrossRef Hu JC, Williams SB, O’Malley AJ, Smith MR, Nguyen PL, Keating NL. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol. 2012;61:1119–28.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol. 2010;58:831–5.PubMedCrossRef Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol. 2010;58:831–5.PubMedCrossRef
13.
Zurück zum Zitat Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011;29:2185–90.PubMedCrossRef Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011;29:2185–90.PubMedCrossRef
14.
Zurück zum Zitat Adamy A, Yee DS, Matsushita K, Maschino A, Cronin A, Vickers A, et al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol. 2011;185:477–82.PubMedCentralPubMedCrossRef Adamy A, Yee DS, Matsushita K, Maschino A, Cronin A, Vickers A, et al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol. 2011;185:477–82.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302:1202–9.PubMedCentralPubMedCrossRef Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302:1202–9.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, SPCG-4 Investigators, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364:1708–17.PubMedCrossRef Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, SPCG-4 Investigators, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364:1708–17.PubMedCrossRef
17.
Zurück zum Zitat Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Prostate Cancer Intervention versus Observation Trial (PIVOT) study group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203–13.PubMedCentralPubMedCrossRef Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Prostate Cancer Intervention versus Observation Trial (PIVOT) study group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203–13.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. American Joint Committee on Cancer (AJCC) cancer staging manual. 7th ed. New York, NY 2010. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. American Joint Committee on Cancer (AJCC) cancer staging manual. 7th ed. New York, NY 2010.
19.
Zurück zum Zitat Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Prostate Cancer Clinical Trials Working Group, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–59.PubMedCentralPubMedCrossRef Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Prostate Cancer Clinical Trials Working Group, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–59.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics. 1982;38:933–42.PubMedCrossRef Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics. 1982;38:933–42.PubMedCrossRef
22.
Zurück zum Zitat Studer UE, Whelan P, Wimpissinger F, Casselman J, de Reijke TM, Knönagel H, et al., EORTC Genitourinary Cancer Group. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up. Eur Urol. 2013. doi:10.1016/j.eururo.2013.07.024. Studer UE, Whelan P, Wimpissinger F, Casselman J, de Reijke TM, Knönagel H, et al., EORTC Genitourinary Cancer Group. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up. Eur Urol. 2013. doi:10.​1016/​j.​eururo.​2013.​07.​024.
23.
Zurück zum Zitat McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int. 2006;97:247–54.PubMedCrossRef McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int. 2006;97:247–54.PubMedCrossRef
24.
Zurück zum Zitat Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300:173–81.PubMedCentralPubMedCrossRef Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300:173–81.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Wong YN, Freedland SJ, Egleston B, Vapiwala N, Uzzo R, Armstrong K. The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol. 2009;56:609–16.PubMedCentralPubMedCrossRef Wong YN, Freedland SJ, Egleston B, Vapiwala N, Uzzo R, Armstrong K. The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol. 2009;56:609–16.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Akaza H, Homma Y, Usami M, Hirao Y, Tsushima T, Okada K, Prostate Cancer Study Group, et al. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int. 2006;98:573–9.PubMedCrossRef Akaza H, Homma Y, Usami M, Hirao Y, Tsushima T, Okada K, Prostate Cancer Study Group, et al. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int. 2006;98:573–9.PubMedCrossRef
27.
Zurück zum Zitat Ueno S, Namiki M, Fukagai T, Ehara H, Usami M, Akaza H. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Int J Urol. 2006;13:1494–500.PubMedCrossRef Ueno S, Namiki M, Fukagai T, Ehara H, Usami M, Akaza H. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Int J Urol. 2006;13:1494–500.PubMedCrossRef
28.
Zurück zum Zitat Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, NCIC CTG PR.3/MRC UK PR07 investigators, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378:2104–11.PubMedCentralPubMedCrossRef Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, NCIC CTG PR.3/MRC UK PR07 investigators, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378:2104–11.PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373:301–8.PubMedCrossRef Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373:301–8.PubMedCrossRef
30.
Zurück zum Zitat Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306:2359–66.PubMedCrossRef Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306:2359–66.PubMedCrossRef
Metadaten
Titel
Survival following primary androgen deprivation therapy for localized intermediate- or high-risk prostate cancer: comparison with the life expectancy of the age-matched normal population
verfasst von
Kazuhiro Matsumoto
Masayuki Hagiwara
Nobuyuki Tanaka
Nozomi Hayakawa
Masaru Ishida
Akiharu Ninomiya
Yosuke Nakajima
So Nakamura
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 6/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0979-3

Weitere Artikel der Ausgabe 6/2014

Medical Oncology 6/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.